These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 32385703)

  • 1. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
    Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
    PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
    Chen P; Ma A; Liu Q
    Clin Drug Investig; 2018 Nov; 38(11):1031-1039. PubMed ID: 30194584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Elbasha E; Greaves W; Roth D; Nwankwo C
    J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    Suenaga R; Suka M; Hirao T; Hidaka I; Sakaida I; Ishida H
    PLoS One; 2021; 16(4):e0248748. PubMed ID: 33793594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
    McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
    Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
    Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
    Lu Y; Jin X; Duan CA; Chang F
    PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
    Li X; Chan NS; Tam AW; Hung IFN; Chan EW
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1801-1809. PubMed ID: 28516201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
    Virabhak S; Yasui K; Yamazaki K; Johnson S; Mitchell D; Yuen C; Samp JC; Igarashi A
    J Med Econ; 2016 Dec; 19(12):1144-1156. PubMed ID: 27348464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    Fathi H; Clark A; Hill NR; Dusheiko G
    BMC Infect Dis; 2017 Nov; 17(1):722. PubMed ID: 29145802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
    Due OT; Thakkinstian A; Thavorncharoensap M; Sobhonslidsuk A; Wu O; Phuong NK; Chaikledkaew U
    Value Health; 2020 Sep; 23(9):1180-1190. PubMed ID: 32940236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.